For Immediate Release
Understanding Tears and Regulation of Lacrimal Gland Secretions
Contact: Kathryn Ryan
New Rochelle, NY, December 29, 2016–The lacrimal gland of the eye secretes a major component of tears, yet surprisingly little is still understood about the signaling pathways that activate lacrimal gland secretions. The most current knowledge of how purinergic receptors affect the function of the lacrimal gland and interact with neurotransmitters is presented in a review article published in Journal of Ocular Pharmacology and Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Ocular Pharmacology and Therapeutics website until January 26, 2017.
Robin Hodges and Darlene Dartt, Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School, Boston, MA are coauthors of the article entitled "Signaling Pathways of Purinergic Receptors and Their Interactions with Cholinergic and Adrenergic Pathways in the Lacrimal Gland." They discuss and interpret recent research findings on the signaling pathways activated by the purinergic receptors present on the lacrimal gland. Other key topics include the regulation of lacrimal gland secretion, the potential role this regulatory activity could play in normal and pathological responses of the lacrimal gland, and mechanisms of crosstalk between purinergic and other types of receptors.
"This is a well-written, comprehensive review that nicely summarizes a complex and important area of research relevant to dry-eye disease," says Editor-in-Chief W. Daniel Stamer, PhD, Joseph A. C. Wadsworth Professor of Ophthalmology and Professor of Biomedical Engineering, Duke University, Durham, NC.
Research reported in this publication was supported by the National Institutes of Health under Award Numbers R01 EY06177 and P30 EY00379035. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Journal of Ocular Pharmacology and Therapeutics is an authoritative peer-reviewed journal published ten times a year online with open access options and in print. It is the only multidisciplinary, peer-reviewed journal providing basic and clinical research that focuses on biopharmaceuticals that have the potential to prevent, treat, and/or diagnose ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of biopharmaceuticals for the treatment of ophthalmic disorders. Tables of content and a sample issue may be viewed on the Journal of Ocular Pharmacology and Therapeutics website. Journal of Ocular Pharmacology and Therapeutics is the official journal of the Association for Ocular Pharmacology and Therapeutics.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including ASSAY and Drug Development Technologies and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.